We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT).
introduction Long-term central vein catheters (CVCs) are of widespread use in patients with malignancy. CVC use, however, is associated with an increased risk of infections [1] and deep vein thrombosis (DVT) [2] . Both may lead to significant morbidity.
The incidence of CVC-related DVT in adult patients with cancer varies considerably (from 0% to 66%) in various studies [3, 4] . In particular, marked differences relate to whether clinical symptomatic thrombosis or both symptomatic and asymptomatic thrombosis, as assessed by routine screening venography, was used as the end point of the study [4] .
When this study was planned, only two open-label randomized controlled trials had been carried out to evaluate the clinical benefit of antithrombotic prophylaxis for central vein catheter-related thrombosis (CVCrT) in patients with cancer [5, 6] . Both found that a low fixed dose of warfarin or dalteparin 2500 U once a day for 90 days were effective and safe in preventing CVCrT. Subsequent studies, mainly focused on symptomatic CVCrT, produced conflicting conclusions regarding the efficacy of routine primary thromboprophylaxis in these patients [7] [8] [9] [10] [11] [12] .
We carried out a randomized controlled trial to assess the efficacy and safety of an 'early' and 'short-term' prophylaxis with an oral anticoagulant, acenocumarine or a low-molecular weight heparin (LMWH), dalteparin, for the prevention of venous thromboembolism (VTE) in cancer patients with CVC. In this study, serial venographies were used to assess the timing and the rate of CVCrT and the evolution of non-occlusive CVCrT.
patients and methods

study patients
Consecutive cancer patients who were 18 years of age or older with a life expectancy of at least 3 months and who were scheduled for CVC insertion for chemotherapy administration were eligible.
Exclusion criteria included previous CVC insertion; known hypersensitivity to X-ray contrast; renal failure (serum creatinine level >180 lmol/l); active gastric peptic ulcer or severe hepatic disease; DVT in the previous 3 months or cerebral bleeding in the previous 6 months; known cerebral metastasis; bleeding disorders [activated partial thromboplastin time (aPTT) 30% longer than the control value and international normalized ratio (INR) > 1.5]; platelet count <80 · 10 9 /l; antithrombin III <60%; treatment with unfractionated heparin, LMWH, oral anticoagulants or antiplatelet agents within 5 days before CVC insertion; pregnancy and refusal to give written consent. The study protocol was approved by the local ethical committee and patients gave written informed consent before randomization.
Long-term silicone tunneled exteriorized or totally implanted catheters of 6.6-9.6 French were allowed. The access point was the right or left subclavian vein, and the correct position of the catheter tip was confirmed by chest X-ray.
study design and treatment plan
This was a randomized controlled trial. Eligible patients were randomly assigned to receive either acenocumarine (Sintrom; Novartis Pharmaceutical, Origgio, Italy) 1 mg/day for 3 days before and 8 days after CVC insertion (group A) or dalteparin (Fragmin; Farmacia Italia, Milan, Italy) 5000 IU 2 h before and daily for 8 days after CVC insertion (group D) or no anticoagulant treatment (group NT).
Randomization was carried out ‡4 days before CVC insertion. Permuted blocks of four were used for treatment allocation. In Group A patients, the INR value determination was mandatory on the day of CVC insertion, and if it was >1.5, the patient did not undergo CVC insertion. Patients who developed any medical condition requiring therapeutic anticoagulation after enrollment stopped the study medication and were analyzed according to their initial anticoagulant treatment assignment.
assessment of end points
The primary efficacy end point of this study was CVCrT confirmed by venography. Venography was carried out using a nonionic contrast agent infused in an antecubital vein of the arm ipsilateral to the CVC and was scheduled on days 8 and 30 after CVC insertion, and then every 2 months for three times or earlier if there was a clinical suspicion of CVCrT, pulmonary embolism (PE) or compulsory catheter removal. CVCrT was defined as an intraluminal filling defect repeatedly seen on two or more views in either the veins in which the CVC was positioned or the contiguous veins.
Based on the occlusion degree of the vein's lumen, CVCrT was considered as grade 1 when the thrombus occupied less than half of the lumen, grade 2 when it occupied more than half of the lumen and grade 3 when the lumen was completely obstructed by the thrombus with evidence of collateral vessels (Figure 1 ). Grades 1 and 2 were regarded as non-occlusive, while grade 3 was occlusive CVCrT.
Venograms were evaluated independently by two radiologists who were unaware of the patients' clinical status and the assigned treatment, immediately after venography had been carried out. Whenever disagreement occurred, consensus was reached through collegial discussion and, when necessary, other venograms, sometimes bilateral, were carried out.
Secondary efficacy end points were clinically overt PE, confirmed by high probability ventilation-perfusion lung scanning or by multislice computed tomography and death.
The main safety end point was major bleeding. This was defined as clinically overt bleeding associated with a decrease in the hemoglobin level of at least 2 g/dl or requiring the transfusion of two or more units of packed red cells in any 24-h period. Retroperitoneal and intracranial bleeding and any other hemorrhage requiring surgical intervention were also considered as major. Any other bleeding was considered as minor.
All bleeding episodes and deaths with their causative pathology were adjudicated by two physicians blinded to the treatment assignments.
surveillance program and follow-up
The first month after CVC insertion, patients were assessed weekly to review their clinical status, symptoms and signs of VTE, bleeding and other adverse events. Before each scheduled venography, blood sampling for measuring hemoglobin, platelets, complete blood cell count, liver enzymes, creatinine level, aPTT and INR was carried out.
In case of symptoms and/or signs suggestive of VTE, patients were instructed to contact the investigators and, if the clinical suspicion of CVCrT was confirmed, venography was immediately carried out. If an occlusive CVCrT was revealed, the patients were treated with thrombolytics and/or unfractionated heparin or LMWH followed by oral anticoagulants according to the institutional protocols, and the CVC was preferably left in place. If venography showed non-occlusive CVCrT, the patients were contacted weekly by phone and were instructed to contact the investigators in the case of any clinical symptoms and/or signs suggestive of VTE in order to start timely treatment.
Follow-up started after the second venography or on study withdrawal when this occurred. The duration of follow-up for all patients was 2 months. During this period, the patients were monitored by telephone contacts, by means of hospital visits during chemotherapy treatment, and at scheduled venography to record the occurrence of clinically overt VTE, bleeding or death. For patients who underwent venography after 3 months from CVC insertion, follow-up continued until the last carried out venography, i.e. 150 or 210 days after CVC insertion or catheter withdrawal. After the last venography, the treatment of non-occlusive CVCrT was left to the discretion of the attending physician.
statistical analysis
The primary efficacy analysis compared the rate of CVCrT as screened by mandatory venography in patients receiving acenocumarine, dalteparin or NT. 
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Data analysis was carried out on an intent-to-treat basis. The intent-totreat population was defined as all randomized patients who underwent CVC insertion and the first venography.
The safety analysis compared the rate of bleeding in the three groups (acenocumarine, dalteparin and NT). All patients who received at least one dose of study medication or who underwent CVC insertion (group NT) were included in the safety analysis.
The sample size was based on the estimated rates of CVCrT in the three groups. On the basis of previous venography studies [5, 6] , an incidence of CVCrT of 45% in group NT and of 25% in group A or D was assumed. To demonstrate this 45% risk reduction with an a of 5% and a b of 90% in a two-sided test, 120 patients for each group were required. Assuming a dropout rate of 25% of enrolled patients, a total of 450 patients were to be included in the study.
Comparison of proportions was done by means of chi-square analysis. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were obtained by means of unconditional multiple logistic regression model [13] . All P values were two sided. results patients Four hundred and fifty patients were randomized at our institute from February 2000 to June 2004. One hundred and fifty were assigned to group A, 150 to group D and 150 to group NT. The overall dropout rate was 22.7% ( Figure 2) . The causes and number of dropouts in the three study groups are reported in Table 1 . Seven patients in group A, nine patients in group D and 12 patients in group NT did not undergo CVC insertion (Table 1 ). The primary efficacy population was 77.3% (348 of 450 patients): 76% in group A, 80% in group D and 76% in group NT (Figure 2 ). The three treatment groups were well balanced in terms of demographic characteristics, cancer site, cancer histology, cancer stage and CVC characteristics ( Table 2) .
venous thromboembolism
All patients of the primary efficacy population underwent at least two venographies. Overall, the rate of venographydetected CVCrT 8 days after catheter insertion was 37.4%; the extent of non-occlusive and occlusive CVCrT was 36.2% and 1.15%, respectively (Table 3) . Thirty days after CVC insertion, the cumulative rate of CVCrT was 38.2%; the rate of nonocclusive and occlusive CVCrT was 36.2% and 2.0%, respectively.
The rates of non-occlusive, occlusive and overall CVCrT in the three study groups, 8 and 30 days after CVC insertion, are reported in Table 4 . Both acenocumarine and dalteparin reduced the rate of both overall and non-occlusive CVCrT as compared with no anticoagulant treatment, while acenocumarine was more effective than dalteparin (Table 5) . No differences between the three groups were observed in the rate of occlusive CVCrT (Table 5) .
Altogether, 265 patients underwent three venographies, 211 patients four and 143 patients five venographies at 3, 5 and 7 months after CVC insertion, respectively. Between the first and the seventh month, only three new cases (one at the third and two at the fifth month, all in group NT) of non-occlusive CVCrT were observed. In addition, four cases of non-occlusive CVCrT became occlusive (two in group D and two in group NT).
Overall, 11 cases (3.2%) of occlusive CVCrT were observed during the study and the follow-up period: one in group A, six in group D and four in group NT. The rate of symptomatic CVCrT was 2.0% without any difference between the groups: 0.9% group A, 2.5% group D and 2.6% group NT, P = 0.57. All symptomatic thromboses were occlusive CVCrTs. Four of 11 patients (36%) with occlusive thrombosis were asymptomatic.
In two cases in which the CVCrT occluded both the subclavian and the innominate veins, the catheter was withdrawn. In all other cases of occlusive CVCrT, the catheter was left in situ.
None of the patients with a CVCrT presented clinical signs or symptoms of PE.
timing and evolution of CVC-related DVT One hundred and thirty out of 136 patients (95.6%) who developed CVCrT during the study and the follow-up period had a venography-confirmed CVCrT on day 8 after CVC insertion. Altogether, three new cases of CVCrT between days 8 and 30 (two in group D and one in group A) and three during the follow-up period (group NT) were observed. Between days 8 and 30, the occlusion degree of non-occlusive CVCrT increased in 4.2% (1 of 24), 4.3% (2 of 46) and 6.7% (4 of 60) of groups A, D and NT patients, respectively. Similar percentages of occlusion degree increase were seen in each of the subsequent venography controls (data not shown). A spontaneous disappearance or reduction of the occlusion degree of non-occlusive CVCrT was observed during the follow-up period in three cases: 2 of 39 (5%) in group D and 1 of 49 (2%) in group NT. safety There were no significant adverse effects associated with the use of acenocumarine or dalteparin at doses employed in the study. One hundred and forty-three patients in group A (95.3%) and 
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141 in group D (94.0%) completed the study drug administration or took at least one dose of the study medication, and 138 patients in group NT (92.0%) underwent CVC insertion. No major bleeding was observed in either group during the study and the follow-up periods. Three episodes of minor bleeding were observed in group A, three in group D and four in group NT during the follow-up period. There were two (1,4%) interruptions of study medication in group A due to prolonged INR values (1.84 and 4.6) after 3 days of treatment. Moreover, 8 days after CVC insertion, 14 of 138 (10.1%) group A patients who completed the study drug administration showed an INR value >1.50: median value 2.46, range 1.57-5.29. Similar INR variations were seen in 3 of 138 (2.2%) group NT patients (P = 0.01). Four of 141 (2.8%) group D patients who completed the study drug administration presented an aPTT ratio >1.3 (range 1.33-2.56). Similar aPTT alterations were registered in 3 of 138 (2.2%) group NT patients (P = 0.72).
deaths
During the follow-up period, 13 patients in group A, 11 in group D and 10 in group NT died from cancer progression; three patients died from cardiac failure, one in each group. No differences were observed between the groups [14 of 143 (9.8%) group A, 12 of 141 (8.5%) group D, 11 of 138 (7.8%) group NT; P = 0.87].
discussion
In the last years, studies mainly focused on symptomatic CVCrT have produced conflicting conclusions regarding the efficacy of primary thromboprophylaxis in cancer patients bearing a CVC [7] [8] [9] [10] [11] [12] . Consequently, the American College of Chest Physicians guidelines noted that current evidence does not support the routine use of prophylaxis to prevent CVCrT [14] . These suggestions have been reinforced by results of more recent studies that failed to demonstrate the efficacy of longterm prophylaxis of CVCrT [15] [16] [17] . Unfortunately, results of most of the large randomized studies carried out to date [9, 16, 17] might have an important limitation, i.e. the late and quite irregular initiation of antithrombotic prophylaxis following the catheter insertion. Thus, authors may not have observed a benefit of prophylaxis because medication was started after the initiation of the pathophysiologic events leading to thrombosis. In fact, it has been emphasized that during the first hours or days after CVC insertion, cancer patients are at particularly high risk for CVCrT [2, [18] [19] [20] [21] . This is the first study that evaluated the efficacy and safety of an early and short-term prophylaxis for the prevention of CVCrT as well as scheduled serial venographies to assess not only the timing and rate of occlusive and non-occlusive CVCrT but also the evolution of non-occlusive ones.
The results of the study confirmed our previous observation that in the cancer population CVCrT is an early event [2] . In fact, most patients (95.6%) who developed CVCrT during the study and the follow-up period had a venography-confirmed CVCrT (mostly of the subclavian vein) already at day 8 after CVC insertion, probably because of direct vessel wall trauma or endothelial injury which predisposes to thrombosis, in particular during the first hours or days after CVC insertion when the repair processes are not yet concluded [22] . This evidence emphasizes the importance of starting antithrombotic prophylaxis before CVC insertion. On the other hand, this approach appeared safe since we did not observe any bleeding complications associated with the procedure of CVC insertion.
Thirty days after catheterism, the rate of CVCrT in the control group (52,6%) was similar to rates observed in previous venography studies [2, 6, [23] [24] [25] , but higher than that of a more recent report (18%) [15] . This difference is probably due to the fact that in our study, very small thrombi (grade 1, see text), maybe neglected by other authors, were also taken into consideration and that only the subclavian vein was used for CVC insertion, allowing for the best evaluation of CVCrT by venography.
In our study, the early and short-term prophylaxis with either acenocumarine (OR 0.3, P < 0.01) or dalteparin (OR 0.6, original article Annals of Oncology P = 0.05) reduced the risk of CVCrT, while acenocumarine was more effective than dalteparin (OR 0.4, P = 0.01). However, it should be emphasized that this preventive effect was observed on the rate of non-occlusive CVCrT, while the rate of occlusive CVCrTs was so low (overall 3.2%, symptomatic 2.0%) that meaningful differences could not be detected. Most studies on the prophylaxis of CVCrT are focused on occlusive/symptomatic thrombosis, perhaps because of the high risk of pulmonary embolism. However, there is a substantial variation among studies in the reported rates of PE [4, 26] , and the evolution of non-occlusive CVCrT is uncertain. Different from a study on children with malignancies [27] , in our trial only rare cases of non-occlusive CVCrT were transient. On the contrary, 7% of non-occlusive CVCrTs presented an increase of their occlusion degree and roughly half of these became occlusive. Probably, early and short-term prophylaxis, by decreasing the rate of non-occlusive CVCrT, could reduce the occlusive ones. Moreover, this approach would avoid the bleeding risk associated with a long-term prophylaxis (i.e. platelet nadir during chemotherapy), and in particular, the risk observed with the concomitant use of long-term unmonitored minidose warfarin and fluorouracil [28] or the FOLFOX regimen [29] .
In conclusion, our data showed that the frequency of CVCrT, mostly non-occlusive DVT, in cancer patients is higher than recently reported. The first days following CVC insertion are at the highest risk for CVCrT. The early and short-term prophylaxis was effective in reducing venography-detected CVCrT, and acenocumarine was more effective than dalteparin. The doses of the prophylactic agents used in this study proved to be safe, but 10% of patients in the acenocumarine group showed a significant INR variation. Future studies should explore, through the use of an early and short-term scheme, whether new drugs are more effective and also safer.
Whether the low frequency of symptomatic and the high frequency of non-occlusive asymptomatic CVCrT justify a thrombosis prophylaxis in all cancer patients requiring a CVC for chemotherapy is not clarified by this study. It is possible, however, that patients with specific risk factors [30] for thrombosis may have an elevated risk of developing symptomatic CVCrT, making them suitable candidates for prophylaxis. In addition, larger trials to evaluate the risks of non-occlusive asymptomatic CVC-related DVT are warranted. 
